Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895

A framework for variation discovery and genotyping using next-generation DNA sequencing data

DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457

dbSNP: the NCBI database of genetic variation

Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor

Söker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,493

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417

Chimeric Antigen Receptor Therapy

June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,525

Mechanisms of resistance to CAR T cell therapy

Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 999

Recent advances and discoveries in the mechanisms and functions of CAR T cells

Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852

An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer

Feins, S., Kong, W., Williams, E. F., Milone, M. C., & Fraietta, J. A. (2019) · American Journal of Hematology · doi:10.1002/ajh.25418 · Cited by 614

Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering

Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04246 · Cited by 636

Tumor Immunology and Tumor Evolution: Intertwined Histories

Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 564

CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity

Fu, W., Lei, C., Liu, S., Cui, Y., Wang, C., Qian, K., Li, T., Shen, Y., Fan, X., Lin, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12321-3 · Cited by 510

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

Schubert, M., Schmitt, M. W., Wang, L., Ramos, C. A., Jordan, K., Müller‐Tidow, C., & Dreger, P. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.478 · Cited by 502

Engineering and Design of Chimeric Antigen Receptors

Guedan, S., Calderón, H., Posey, A. D., & Maus, M. V. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.009 · Cited by 469

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

Hayden, P. J., Roddie, C., Bader, P., Basak, G. W., Bonig, H. B., Bonini, C., Chabannon, C., Ciceri, F., Corbacioglu, S., Ellard, R., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.003 · Cited by 486

γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer

Silva‐Santos, B., Mensurado, S., & Coffelt, S. B. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0153-5 · Cited by 434

Recent advances in CAR-T cell engineering

Huang, R., Li, X., He, Y., Zhu, W., Gao, L., Liu, Y. Z., Gao, L., Qin, W., Zhong, J. F., Zhang, C., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00910-5 · Cited by 412

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 460

Emerging Cellular Therapies for Cancer

Guedan, S., Ruella, M., & June, C. H. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041407 · Cited by 394

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J., & Germeraad, W. T. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01083-5 · Cited by 379

Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells

Cordeiro, A., Bezerra, E. D., Hirayama, A. V. V., Hill, J. A., Wu, Q. V., Voutsinas, J. M., Sorror, M. L., Turtle, C. J., Maloney, D. G., & Bar, M. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.08.003 · Cited by 373

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Dimitri, A. J., Herbst, F., & Fraietta, J. A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01559-z · Cited by 379

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01702-9 · Cited by 349

Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

Abou-el-Enein, M., Elsallab, M., Feldman, S. A., Fesnak, A. D., Heslop, H. E., Marks, P., Till, B. G., Bauer, G., & Savoldo, B. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0084 · Cited by 321

Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction

Singh, N., Lee, Y. G., Shestova, O., Ravikumar, P., Hayer, K. E., Hong, S. J., Lu, X. M., Pajarillo, R., Agarwal, S., Kuramitsu, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0813 · Cited by 295

CAR-T cell manufacturing: Major process parameters and next-generation strategies

Ceja, M. A., Khericha, M., Harris, C. M., Puig-Saus, C., & Chen, Y. Y. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230903 · Cited by 349

Universal CARs, universal T cells, and universal CAR T cells

Zhao, J., Lin, Q., Song, Y., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0677-2 · Cited by 324

T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

Ghilardi, G., Fraietta, J., Gerson, J., Deerlin, V. V., Morrissette, J. J. D., Caponetti, G. C., Paruzzo, L., Harris, J., Chong, E. A., Susanibar-Adaniya, S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02826-w · Cited by 249

Hypoxia as a driver of resistance to immunotherapy

Kopecka, J., Salaroglio, I. C., Pérez-Ruiz, E., Sarmento‐Ribeiro, A. B., Saponara, S., Rivas, J. D. L., & Riganti, C. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100787 · Cited by 264

Genetically engineered T cells for cancer immunotherapy

Li, D., Li, X., Zhou, W.-L., Huang, Y., Liang, X., Jiang, L., Yang, X., Sun, J., Li, Z., Han, W., et al. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0070-9 · Cited by 251

The journey of CAR-T therapy in hematological malignancies

Lu, J., & Jiang, G. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01663-0 · Cited by 240

Applications of Surface Modification Technologies in Nanomedicine for Deep Tumor Penetration

Li, Z., Shan, X., Chen, Z., Gao, N., Zeng, W., Zeng, X., & Mei, L. (2020) · Advanced Science · doi:10.1002/advs.202002589 · Cited by 221

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

Siddiqi, T., Maloney, D. G., Kenderian, S. S., Brander, D. M., Dorritie, K. A., Soumerai, J. D., Riedell, P. A., Shah, N. N., Nath, R., Fakhri, B., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01052-8 · Cited by 211

CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy

Pillai, V., Muralidharan, K., Meng, W., Bagashev, A., Oldridge, D. A., Himeles, J. R., Arnam, J. V., Melenhorst, J. J., Mohan, D., DiNofia, A. M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000692 · Cited by 210

Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response

Baeuerle, P. A., Ding, J. P., Patel, E. S., Thorausch, N., Horton, H. M., Gierut, J. J., Scarfò, I., Choudhary, R., Kiner, O., Krishnamurthy, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10097-0 · Cited by 212

Advances in Universal CAR-T Cell Therapy

Lin, H., Cheng, J., Mu, W., Zhou, J., & Zhu, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744823 · Cited by 215

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia

Ottaviano, G., Georgiadis, C., Gkazi, S. A., Syed, F., Zhan, H., Etuk, A., Preece, R., Chu, J., Kubat, A., Adams, S. P., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq3010 · Cited by 212

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Plaks, V., Rossi, J. M., Chou, J., Wang, L., Poddar, S., Han, G., Wang, Z., Kuang, S.-Q., Chu, F., Davis, R. E., et al. (2021) · Blood · doi:10.1182/blood.2021010930 · Cited by 199

Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities

Magnani, C. F., Gaipa, G., Lussana, F., Belotti, D., Gritti, G., Napolitano, S., Matera, G., Cabiati, B., Buracchi, C., Borleri, G., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138473 · Cited by 201

Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells

Singh, N., Frey, N. V., Engels, B., Barrett, D. M., Shestova, O. E., Ravikumar, P., Cummins, K. D., Lee, Y. G., Pajarillo, R., Chun, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01326-5 · Cited by 199

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Jain, T., Bar, M., Kansagra, A. J., Chong, E. A., Hashmi, S. K., Neelapu, S. S., Byrne, M. T., Jacoby, E., Lazaryan, A., Jacobson, C. A., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.08.015 · Cited by 196

2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies

Xu, Y., Liu, Q., Zhong, M., Wang, Z., Chen, Z., Zhang, Y., Xing, H., Tian, Z., Tang, K., Liao, X., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0732-7 · Cited by 196

From concept to cure: The evolution of CAR-T cell therapy

Patel, K. K., Tariveranmoshabad, M., Kadu, S., Shobaki, N., & June, C. H. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.005 · Cited by 211

Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells

Billingsley, M. M., Hamilton, A. G., Mai, D., Patel, S. K., Swingle, K. L., Sheppard, N. C., June, C. H., & Mitchell, M. J. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c02503 · Cited by 188

Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies

Ruella, M., Korell, F., Porazzi, P., & Maus, M. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00807-1 · Cited by 197

Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells

Bishop, D. C., Clancy, L. E., Simms, R., Burgess, J., Mathew, G., Moezzi, L., Street, J. A., Sutrave, G., Atkins, E., McGuire, H. M., et al. (2021) · Blood · doi:10.1182/blood.2021010813 · Cited by 177

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

Shah, N. N., Maatman, T. C., Hari, P., & Johnson, B. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00146 · Cited by 181

PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges

McGowan, E. M., Lin, Q., Ma, G., Yin, H., Chen, S., & Lin, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109625 · Cited by 182

AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia

Nawaz, W., Huang, B., Xu, S., Li, Y., Zhu, L., Hu, Y., Wu, Z., & Wu, X. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00508-1 · Cited by 173

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects

Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 181

Genetic engineering of T cells for immunotherapy

Ellis, G. I., Sheppard, N. C., & Riley, J. L. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00329-9 · Cited by 170

Cell therapies in the clinic

Wang, L. L., Janes, M. E., Kumbhojkar, N., Kapate, N., Clegg, J. R., Prakash, S., Heavey, M. K., Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10214 · Cited by 162

Nanomedicine‐Boosting Tumor Immunogenicity for Enhanced Immunotherapy

Huang, J., Yang, B., Peng, Y., Huang, J., Wong, S. H. D., Bian, L., Zhu, K., Shuai, X., & Han, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202011171 · Cited by 160

Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study

Sheykhhasan, M., Manoochehri, H., & Dama, P. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00418-1 · Cited by 165

Nanomedicine and macroscale materials in immuno-oncology

Sun, Q., Barz, M., Geest, B. G. D., Diken, M., Hennink, W. E., Kiessling, F. M., Lammers, T., & Shi, Y. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00473k · Cited by 155

Engineered off-the-shelf therapeutic T cells resist host immune rejection

Mo, F., Watanabe, N., McKenna, M. K., Hicks, J. M., Srinivasan, M., Gomes‐Silva, D., Atilla, E., Smith, T. S., Atilla, P. A., Ma, R., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0601-5 · Cited by 155

The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19

Brændstrup, P., Levine, B. L., & Ruella, M. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2019.12.004 · Cited by 163

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells

Morgan, M. A., Büning, H., Sauer, M. G., & Schambach, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01965 · Cited by 153

Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives

Labbé, R. P., Vessillier, S., & Rafiq, Q. A. (2021) · Viruses · doi:10.3390/v13081528 · Cited by 163

3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells

Wang, Z., McWilliams‐Koeppen, H. P., Reza, H., Ostberg, J. R., Chen, W., Wang, X., Huynh, C., Vyas, V., Chang, W.-C., Starr, R., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.02.009 · Cited by 148

The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma

Wei, J., Liu, Y., Wang, C., Zhang, Y., Tong, C., Dai, G., Wang, W., Rasko, J. E. J., Melenhorst, J. J., Qian, W., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00256-x · Cited by 146

Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy

Stock, S., Schmitt, M. W., & Sellner, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246223 · Cited by 146

Engineering-enhanced CAR T cells for improved cancer therapy

Milone, M. C., Xu, J., Chen, S., Collins, M. A., Zhou, J., Powell, D. J., & Melenhorst, J. J. (2021) · Nature Cancer · doi:10.1038/s43018-021-00241-5 · Cited by 148

Toxicities of CD19 CAR‐T cell immunotherapy

Hirayama, A. V. V., & Turtle, C. J. (2019) · American Journal of Hematology · doi:10.1002/ajh.25445 · Cited by 144

CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells

Alcantara, M., Tesio, M., June, C. H., & Houot, R. (2018) · Leukemia · doi:10.1038/s41375-018-0285-8 · Cited by 142

In vivo chimeric antigen receptor (CAR)-T cell therapy

Bot, A., Scharenberg, A. M., Friedman, K. M., Guey, L. T., Hofmeister, R., Andorko, J. I., Klichinsky, M., Neumann, F., Shah, J. V., Swayer, A. J., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01291-5 · Cited by 172

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

Razeghian, E., Nasution, M. K. M., Rahman, H. S., Gardanova, Z. R., Abdelbasset, W. K., Surendar, A., Bokov, D. O., Suksatan, W., Nakhaei, P., Shariatzadeh, S., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02510-7 · Cited by 147

Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL

Diorio, C. J., Murray, R. C., Naniong, M., Barrera, L. A., Camblin, A. J., Chukinas, J. A., Coholan, L. J., Edwards, A., Fuller, T. J., Gonzales, C., et al. (2022) · Blood · doi:10.1182/blood.2022015825 · Cited by 134

Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients

Marofi, F., Rahman, H. S., Al-Obaidi, Z. M. J., Jalil, A. T., Abdelbasset, W. K., Suksatan, W., Dorofeev, A. E., Shomali, N., Chartrand, M. S., Pathak, Y. V., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02420-8 · Cited by 138

Direct in vivo CAR T cell engineering

Short, L., Holt, R. A., Cullis, P. R., & Evgin, L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.03.004 · Cited by 141

BiTEs better than CAR T cells

Subklewe, M. S. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020001792 · Cited by 129

Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions

Fleischer, L. C., Spencer, H. T., & Raikar, S. S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0801-y · Cited by 127

Nanovaccines with cell-derived components for cancer immunotherapy

Meng, Z., Zhang, Y., Zhou, X., Ji, J., & Liu, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114107 · Cited by 126

Advancing CAR T cell therapy through the use of multidimensional omics data

Yang, J., Chen, Y., Jing, Y., Green, M. R., & Han, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00729-2 · Cited by 130

Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies

Lin, H., Yang, X., Ye, S., Huang, L., & Mu, W. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117252 · Cited by 134

Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering

Michels, K. R., Sheih, A., Hernández, S., Brandes, A., Parrilla, D., Irwin, B., Perez, A. M., Ting, H.-A., Nicolai, C. J., Gervascio, T., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006292 · Cited by 134

Born to survive: how cancer cells resist CAR T cell therapy

Lemoine, J., Ruella, M., & Houot, R. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01209-9 · Cited by 126

Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms

Michels, A., Ho, N., & Buchholz, C. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.018 · Cited by 131

Immunotherapy in pediatric acute lymphoblastic leukemia

Inaba, H., & Pui, C. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09834-0 · Cited by 129

CAR-T cell manufacturing landscape—Lessons from the past decade and considerations for early clinical development

Dias, J., García, J., Agliardi, G., & Roddie, C. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101250 · Cited by 127

The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead

Nelson, A., Lukacs, J., & Johnston, B. (2021) · Cancers · doi:10.3390/cancers13205174 · Cited by 124

Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin’s lymphoma

Yan, Z.-X., Li, L., Wang, W., OuYang, B.-S., Cheng, S., Wang, L., Wu, W., Xu, P.-P., Muftuoglu, M., Hao, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0101 · Cited by 115

Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy

Gutiérrez-Guerrero, A., Cosset, F., & Verhoeyen, E. (2020) · Viruses · doi:10.3390/v12091016 · Cited by 122

CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities

Fischer, J. W., & Bhattarai, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693016 · Cited by 113

Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics

Panch, S. R., Srivastava, S. K., Elavia, N., McManus, A., Liu, S., Jin, P., Highfill, S. L., Li, X., Dagur, P., Kochenderfer, J. N., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.015 · Cited by 107

The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy

Paucek, R. D., Baltimore, D., & Li, G. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.002 · Cited by 104

State of the art in CAR T cell therapy for CD19+ B cell malignancies

Frigault, M. J., & Maus, M. V. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129208 · Cited by 107

Automated manufacture of autologous CD19 CAR-T cells for treatment of non-hodgkin lymphoma

Jackson, Z., Roe, A., Sharma, A. A., Lopes, F. B. T. P., Talla, A., Kleinsorge-Block, S., Zamborsky, K., Schiavone, J., Manjappa, S., Schauner, R., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01941 · Cited by 102

Delivery technologies for T cell gene editing: Applications in cancer immunotherapy

Atsavapranee, E., Billingsley, M. M., & Mitchell, M. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103354 · Cited by 104

Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells

Kath, J., Du, W., Pruene, A., Braun, T., Thommandru, B., Turk, R., Sturgeon, M. L., Kurgan, G., Amini, L., Stein, M., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.018 · Cited by 103

Adoptive Immunotherapy beyond CAR T-Cells

Titov, A., Zmievskaya, E., Ganeeva, I., Valiullina, A., Petukhov, A., Rakhmatullina, A., Рифкатовна, М. Р., Fainshtein, M., Rizvanov, A. A., & Bulatov, E. (2021) · Cancers · doi:10.3390/cancers13040743 · Cited by 101

CAR-T cells: Early successes in blood cancer and challenges in solid tumors

Dana, H., Chalbatani, G. M., Jalali, S. A., Mirzaei, H. R., Grupp, S. A., Suarez, E. R., Rapôso, C., & Webster, T. J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.020 · Cited by 100

Overcoming tumor resistance mechanisms in CAR-NK cell therapy

Valeri, A., García-Ortiz, A., Castellano, E., Córdoba, L., Maroto-Martín, E., Encinas, J., Leivas, A., Río, P., & Martínez‐López, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953849 · Cited by 96

Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?

Seimetz, D., Heller, K., & Richter, J. (2019) · Cell Medicine · doi:10.1177/2155179018822781 · Cited by 90

The Emergence of Universal Immune Receptor T Cell Therapy for Cancer

Minutolo, N. G., Hollander, E. E., & Powell, D. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00176 · Cited by 98

Determinants of response and resistance to CAR T cell therapy

Lesch, S., Benmebarek, M.-R., Cadilha, B. L., Stoiber, S., Subklewe, M. S., Endres, S., & Kobold, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.004 · Cited by 96

Engineering better chimeric antigen receptor T cells

Zhang, H., Zhao, P., & Huang, H. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00190-2 · Cited by 93

Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks

Diorio, C. J., Teachey, D. T., & Grupp, S. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00959-y · Cited by 95

Advancing cell-based cancer immunotherapy through stem cell engineering

Li, Y.-R., Dunn, Z. S., Yu, Y., Li, M., Wang, P., & Yang, L. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.02.009 · Cited by 95

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

Li, C., Mei, H., & Hu, Y. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz042 · Cited by 97

Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma

Panowski, S. H., Srinivasan, S., Tan, N., Tacheva-Grigorova, S. K., Smith, B., Mak, Y. S. L., Ning, H., Villanueva, J., Wijewarnasuriya, D., Lang, S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2931 · Cited by 94

Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies

Xie, B., Li, Z., Zhou, J., & Wang, W. (2022) · Cancers · doi:10.3390/cancers14133230 · Cited by 97

From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy

Pinto, E., Lione, L., Compagnone, M., Paccagnella, M., Salvatori, E., Greco, M., Frezza, V., Marra, E., Aurisicchio, L., Roscilli, G., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06052-3 · Cited by 95

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies

Zhang, Y., Li, C., Du, M., Jiang, H., Luo, W., Tang, L., Kang, Y. J., Xu, J. L., Wu, Z., Wang, X., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00822-w · Cited by 86

Traceless aptamer-mediated isolation of CD8+ T cells for chimeric antigen receptor T-cell therapy

Kacherovsky, N. A., Cardle, I. I., Cheng, E. L., Yu, J. L., Baldwin, M. L., Salipante, S. J., Jensen, M. C., & Pun, S. H. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0411-6 · Cited by 87

Resisting CAR T-cell Therapy: A Case Study

(2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2018-139 · Cited by 1

Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells

Cordes, N., Kolbe, C., Lock, D., Holzer, T., Althoff, D., Schaefer, D., Blaeschke, F., Kotter, B., Karitzky, S., Rössig, C., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.013 · Cited by 19

Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts

Quintarelli, C., Guercio, M., Manni, S., Boffa, I., Sinibaldi, M., Cecca, S. D., Caruso, S., Abbaszadeh, Z., Camera, A., Cembrola, B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001514 · Cited by 10

Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report

Schultz, L. M., Patel, S., Davis, K. L., Ramakrishna, S., Sahaf, B., Bhatia, N., Baggott, C., Erickson, C., Majzner, R. G., Oak, J. S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001073 · Cited by 7

CAR antigens beyond recognition

Harjes, U. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0082-7